Skip to search formSkip to main contentSkip to account menu

SKI-606

Known as: SKI 606, SKI606 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bosutinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or…
On pages 4568, 4572, 4574, and 4576 of the 27 October 2011 issue, there are errors in the text. On page 4568 in the “Study design… 
2012
2012
SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer
Purpose: Src is overexpressed or hyperactivated in a variety of human cancers, including thyroid carcinoma. Src is a central… 
Highly Cited
2011
Highly Cited
2011
Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway That Regulates C/EBPδ Expression and Contributes to Transformation of Breast Tumor Cells
ABSTRACT The transcription factor CCAAT/enhancer-binding protein delta (C/EBPδ, CEBPD) is a tumor suppressor that is… 
Highly Cited
2010
Highly Cited
2010
SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis
In the current study, we have examined the efficacy of a Src/Abl kinase inhibitor SKI-606 (Bosutinib) for its effect on prostate… 
2010
2010
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Abstract 208 Bosutinib is an orally bioavailable dual Src/Abl tyrosine kinase inhibitor (TKI), with minimal inhibitory activity… 
2010
2010
Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).
6502 Background: Bosutinib is an orally bioavailable dual Src/Abl tyrosine kinase inhibitor, with minimal inhibitory activity… 
2009
2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic… 
2009
2009
SKI-606 and beyond
4-Phenylamino-3-quinolinecarbonitriles have been extensively studied by Wyeth as inhibitors of diverse kinases including EGFR… 
2009
2009
Fyn kinase activity is required for normal organization and functional polarity of the mouse oocyte cortex
The objective of the present study was to determine whether Fyn kinase participated in signaling events during sperm–egg… 
Highly Cited
2005
Highly Cited
2005
3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)